Trial reportClinical infectious diseases : an official publication of the Infectious Diseases Society of America2013
Safety and immunogenicity of 2009 pH1N1 vaccination in HIV-infected pregnant women.
Trial report in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00992017 (A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Monovalent Influenza A), which is not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase II Study to Assess the Safety and Immunogenicity of an Inactivated Monovalent Influenza A (H1N1) Vaccine in HIV-1 Infected Pregnant Women
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- A systematic review of ethical issues in vaccine studies involving pregnant women.Human vaccines & immunotherapeutics · 2016Pooled it
- A systematic review of adverse events following immunization during pregnancy and the newborn period.Vaccine · 2015Pooled it
- Immunogenicity and safety of different dosing schedules of trivalent inactivated influenza vaccine in pregnant women with HIV: a randomised controlled trial.The lancet. HIV · 2020Trial
- Kinetics of Hemagglutination-Inhibiting Antibodies Following Maternal Influenza Vaccination Among Mothers With and Those Without HIV Infection and Their Infants.The Journal of infectious diseases · 2015Trial
- Maternal-Child Human Immunodeficiency Virus Clinical Trials Networks across the Ages.Clinics in perinatology · 2024Review
- HIV-related immune activation attenuates polyfunctional IgG and memory B-cell responses to Tdap immunization during pregnancy.EBioMedicine · 2024Observational
- The safety and immunogenicity of vaccines administered to pregnant women living with HIV: a systematic review and meta-analysis.EClinicalMedicine · 2024Article
- Maternal immunisation to improve the health of HIV-exposed infants.The Lancet. Infectious diseases · 2019Review
- H1N1 influenza vaccination in HIV-infected women on effective antiretroviral treatment did not induce measurable antigen-driven proliferation of the HIV-1 proviral reservoir.AIDS research and therapy · 2017Article
- Vaccination of HIV-infected pregnant women: implications for protection of their young infants.Tropical diseases, travel medicine and vaccines · 2017Review
- Maternal vaccination for the prevention of influenza: current status and hopes for the future.Expert review of vaccines · 2016Review
- ETS transcription factors in embryonic vascular development.Angiogenesis · 2016Review
- Transfer of Maternal Antimicrobial Immunity to HIV-Exposed Uninfected Newborns.Frontiers in immunology · 2016Review
- Immune Responses to Circulating and Vaccine Viral Strains in HIV-Infected and Uninfected Children and Youth Who Received the 2013/2014 Quadrivalent Live-Attenuated Influenza Vaccine.Frontiers in immunology · 2016Article
- Heterogeneity of T Cell Responses to Pandemic pH1N1 Monovalent Vaccine in HIV-Infected Pregnant Women.AIDS research and human retroviruses · 2015Article
- Article
- Risk management of seasonal influenza during pregnancy: current perspectives.International journal of women's health · 2014Review
- Cotton rat model for testing vaccines and antivirals against respiratory syncytial virus.Antiviral chemistry & chemotherapyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundPregnant women infected with human immunodeficiency virus (HIV) may have particular vulnerability to 2009 pandemic H1N1 influenza (pH1N1) infection. The safety and immunogenicity of pH1N1 vaccination in HIV-infected pregnant women are unknown.
methodsHIV-infected women 18-39 years of age and 14-34 weeks' gestation on antiretroviral therapy received two 30-μg doses of unadjuvanted, inactivated pH1N1 vaccine 21 days apart. Hemagglutination inhibition titers were measured at entry, 21 days after dose 1, and 10 and 21 days after dose 2, and, in mothers and infants, at delivery and 3 and 6 months postdelivery.
resultsNo severe vaccine-related adverse events were observed among 127 subjects. At entry, 21% had seroprotective (≥1:40) titers. Seroprotection and seroresponse (≥4-fold rise) occurred in 73% and 66% after dose 1 and 80% and 72% after dose 2, respectively. Of women lacking seroprotection at entry, 66% attained seroprotection after dose 1 and 75% after dose 2. Seroprotective titers were present in 67% of mothers and 65% of infants at delivery (median 66 days after dose 2), 60% of mothers and 26% of infants at 3 months postdelivery, and 59% of mothers and 12% of infants at 6 months postdelivery.
conclusionsTwo 30-μg doses were moderately immunogenic in HIV-infected pregnant women. No concerning vaccine-related safety signals were observed. Seroprotection persisted in most women postpartum. Efficient transplacental antibody transfer occurred, but seroprotection in infants waned rapidly. Vaccination to protect HIV-infected pregnant women and their newborns from new influenza strains is feasible, but more immunogenic platforms should be evaluated. Clinical Trials Registration. NCT00992017.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.